Maharashtra FDA Cancels Drug Sale Licences Of Cipla Pharma & Life Sciences’ Pune C&F Unit Over Reactin Plus Irregularities
Mumbai, August 28, 2026: The Maharashtra Food and Drug Administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) unit in Pune over serious irregularities related to the packaging, storage and recall of Reactin Plus Tablets, the regulator said. The FDA said in a statement issued on Friday that the cancellation came into effect on August…
We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- FDA crackdown on Cipla Pharma's Pune unit, license cancelled over 'unauthorised promotional text' hindustantimes.com
- FDA cancels Cipla pharma’s CFA drug sale licence in Pune indianexpress.com
- Maharashtra FDA cancels licence of Cipla's Pune unit economictimes.indiatimes.com
